Dr. Jeremy M. Levin

Chairperson at Ovid Therapeutics

Overview

Dr. Jeremy M. Levin holds the position of Chairperson at Ovid Therapeutics as of January 2026 [1][2]. Levin previously served as Chairperson and CEO of Ovid Therapeutics from June 2015 to December 2025 [9]. Levin has held leadership roles within the Biotechnology Innovation Organization, serving as Chairman of the Board from June 2019 to June 2022 [6] and as Vice Chair Board of Directors from June 2016 to June 2019 [7], and currently holds the position of Board member and Chairman Emeritus as of June 2022 [5]. Levin is also Chairperson at Ceryvyn Therapeutics beginning in June 2022 [4] and a member of the Council on Foreign Relations as of March 2022 [8]. Levin holds a Bachelor of Arts in Zoology from the University of Oxford [10], as well as a Master of Arts and Doctor of Philosophy in Biochemistry and Molecular Biology and Thermodynamics from Oxford [11], and a Bachelor of Medicine and Bachelor of Surgery from the University of Cambridge [12].

Career history

  1. ChairpersonJan 2026 to presentOvid Therapeutics Inc
  2. ChairpersonJan 2021 to presentCeryvyn Therapeutics
  3. ChairpersonJun 2022 to presentCeryvyn Therapeutics
  4. Board member and Chairman EmeritusJun 2022 to presentBiotechnology Innovation Organization
  5. Chairman of the BoardJun 2019 to Jun 2022Biotechnology Innovation Organization
  6. Vice Chair Board Of DirectorsJun 2016 to Jun 2019Biotechnology Innovation Organization
  7. MemberMar 2022 to presentCouncil on Foreign Relations
  8. Chairperson and CEOJun 2015 to Dec 2025Ovid Therapeutics
  9. ChairpersonOvid Therapeutics

Education

  1. Bachelor of Arts (BA), Zoology1971 - 1974University of Oxford
  2. MA and DPhil, Biochemistry and Molecular Biology and Theromdynamics1975 - 1978University of Oxford
  3. Bachelor of Medicine, Bachelor of Surgery (MB BChir)1979 - 1981University of Cambridge

This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.